BioCentury
ARTICLE | Company News

Affimed, Merck deal

February 1, 2016 8:00 AM UTC

Affimed will fund and conduct a Phase Ib trial evaluating its AFM13 with Merck’s melanoma drug Keytruda pembrolizumab to treat relapsed or refractory Hodgkin lymphoma. The trial is expected to begin...